Part 2: Designation and Justification of API Starting Materials: Current Practices across Member Companies of the IQ Consortium-Reference-Cited by-同舟云学术

Part 2: Designation and Justification of API Starting Materials: Current Practices across Member Companies of the IQ Consortium

Author:

Faul Margaret M.¹,Busacca Carl A.²,Eriksson Magnus C.²,Hicks Fred³,Kiesman William F.⁴,Smulkowski Maciej⁵,Orr John D.⁶,Pfeiffer Steven⁷

Affiliation:

1. Chemical Process Research and Development, Amgen Inc., Thousand Oaks, California 91320, United States

2. Chemical Development, Boehringer-Ingelheim Pharmaceuticals, Ridgefield, Connecticut 06877, United States

3. Takeda Pharmaceuticals International Company, Cambridge, Massachusetts 02139, United States

4. Chemical Process Research and Development, Biogen Idec, Cambridge, Massachusetts 02142, United States

5. Chicago Pharmaceutical Science Group, Takeda Development Center Americas, Inc., Deerfield, Illinois 60015, United States

6. US API Process Research and Development, Pharm. Sci. & Tech., Eisai Inc., Andover, Massachusetts 01810, United States

7. Process Development and Manufacturing, Kythera Biopharmaceuticals, Calabasas, California 91301, United States

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Physical and Theoretical Chemistry

Link

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

5. Large‐Scale Synthesis;Burger's Medicinal Chemistry and Drug Discovery;2021-04-26